In recent years, a number of drugs have emerged that have significant cardio-renal protective effects in patients with diabetes, and a typical example is sodium-glucose cotransporter 2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonist (GLP-1RA), and nonsteroidal mineralocorticoid receptor antagonist, finerenone
A sub-analysis of the 29,172 users who disclosed at least one side effect and mentioned a specific formulation found that 17,937 (61.5%) exclusively mentioned semaglutide formulations, and 7125 (24.4%) exclusively mentioned tirzepatide formulations
With access to trial sizes from trusted brands and the ability to earn cashback on your discoveries, you can find what works for your skin without the guesswork
Most GLP-1 medications are administered via subcutaneous injection, either daily or weekly depending on the specific formulation
Others Frequently Asked Questions The global GLP-1 receptor agonist market is projected to be valued at US$ 74.4 Bn in 2026